A Biomimic Nanobullet with Ameliorative Inflammatory Microenvironment for Alzheimer's Disease Treatments

Author:

Wu Yanyue123,Yang Jun123,Geng Yiwan123,Jiao Xiyue12,Lu Zhiguo123,Zhang Tianlu123,Zhao Ruichen123,Guo Jing12,Wang Wenli4,Wang Jing4,Zhang Xin123ORCID

Affiliation:

1. State Key Laboratory of Biochemical Engineering Institute of Process Engineering Chinese Academy of Sciences Beijing 100190 P. R. China

2. Key Laboratory of Biopharmaceutical Preparation and Delivery Chinese Academy of Sciences Beijing 100190 P. R. China

3. School of Chemical Engineering University of Chinese Academy of Sciences Beijing 100049 P. R. China

4. Key Laboratory of Innovative Drug Development and Evaluation School of Pharmacy Hebei Medical University Shijiazhuang 050017 P. R. China

Abstract

AbstractAβ oligomers, formed prior to diagnostic marker‐amyloid β (Aβ) plaques, can damage neurons and trigger neuroinflammation, which accelerate the neuronal injury in Alzheimer's disease (AD). Herein, the combination of eliminating the Aβ oligomers and alleviating the inflammation is a promising therapeutic strategy for AD. However, the presence of the blood‐brain barrier (BBB) and the intrinsic deficiencies of the drugs severely restrict their therapeutic effects. Inspired by the properties of rabies virus, a biomimic nanobullet (PBACR@NRs/SA) targeting neurons has been developed. The biomimic nanobullets possess the BBB penetrating character based on iron oxide nanorods; it can sequentially release rosmarinic acid and small interfering RNA targeting NF‐κB triggered by microenvironment, which improve the microenvironment inflammation and realize the cure for AD. Compared with non‐biomimic systems, the biomimic nanobullets exhibit a less caveolin‐dependent internalization pathway, which reduces ROS production and mitochondrial fission in neurons. Therefore, the biomimic nanobullet is hopeful for the treatment of ADs and provides a promising platform for other brain diseases’ treatments.

Funder

National Natural Science Foundation of China

Publisher

Wiley

Subject

Pharmaceutical Science,Biomedical Engineering,Biomaterials

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号  京ICP备18003416号-3